Jingtai Holdings (02228.HK) subsidiary AILUX announces strategic collaboration with Eli Lilly to empower (AI-driven) bispecific antibody development.

Intelligence Finance APP News, JingTai Holdings (02228.HK) announced that Ailux Shanghai, a wholly-owned subsidiary of JingTai, the world's leading company in AI drug discovery, has reached a platform-based strategic cooperation agreement with Eli Lilly (Lilly) to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases driven by AI.